Skip to main content
. 2018 Feb 2;8:2280. doi: 10.1038/s41598-018-20772-9

Figure 4.

Figure 4

Evaluation of compound 312. (a) Compound 312 elicited dose dependent inhibition of RNP activities of various influenza subtypes. (b) Compound 312 showed inhibition of influenza A/PR/8/34. (c) Viral growth curve with compound 312. Compound 312 could impede influenza A/WSN/33 propagation. (d) MDCK cells were infected with 0.01 MOI A/WSN/33 and incubated with 100 μM compound 312 at various time points. Compound 312 was able to attenuate virus when added post infection. (e) SPR study of compound 312 with PAC. Using the ‘1:1 Langmuir binding’ model by BIAevaluation v. 4.1 software, Kd value was estimated to be 37.7 ± 4.6 μM. Data shown represent the mean ± SD of three independent experiments. *Represents p < 0.05, **Represents p < 0.01. (f) MST study of compound 312 with PAC. Kd value was estimated to be 38.2 ± 5.5 μM by MO.Control software using Kd model.